01 March 2021
Visiongain has published a new report on North American Molecular Diagnostics (MDx) Market Report 2021-2031: Forecasts by Technology (Polymerase Chain Reaction, In Situ Hybridization, Isothermal Nucleic Acid Amplification Technology, Chips and Microarrays, Mass Spectrometry, Sequencing, Transcription Mediated Amplification, Others), by Application (Oncology, Pharmacogenomics, Infectious Diseases, Genetic Testing, Neurological Disease, Cardiovascular Diseases, Microbiology, Others), by Product (Instruments, Reagents), Test Location (Point-of-Care, Over the Counter, Central Laboratories), by Country (USA, Canada) PLUS Analysis of Leading MDx Companies AND COVID-19 Recovery Scenarios.
The North American molecular diagnostics market size was valued at US$ xx million in 2020 and is anticipated to reach US$ xx million in 2026 while growing at a CAGR of xx% during the first half of the forecast period i.e., 2021 to 2026. The regional market size is further projected to reach US$ xx million by 2031 at a CAGR of xx% from 2026 to 2031. The overall CAGR for the regional molecular diagnostics market is expected to be xx% from 2021 to 2031.
COVID-19 Outbreak to Offer Lucrative Growth Opportunities
• Essential Role of Diagnostics in Control of Communicable Diseases
• Growing Public and Clinical Needs to Drive Molecular Diagnostics Market Growth
• Deployment of SARS-CoV-2 Diagnostics Anticipated to Curb the Epidemic Across Geographies
Molecular Diagnostics to Improve Healthcare Outcomes
In order to improve health outcomes, molecular diagnostic testing for genetic or pathogenic diseases is necessary to provide easy, fast and reliable testing, particularly in the developed world. For clinical diagnosis of different pathologies, rapid identification of nucleic acids is important. To avoid undertreatment, it is important to recognise persons who need medication for particular pathologies. The quantity of overtreatment that occurs in resistant micro-organisms can also be minimised. This is anticipated to fuel North American molecular diagnostics market over the forecast period from 2021 to 2031.
Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products to strengthen their position in the North American molecular diagnostics market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the molecular diagnostics market. For example, on 1st September 2020, Biocartis Group NV announced the extension of its partnership with LifeArc, an international medical research charity headquartered in the United Kingdom, with a new arrangement aimed at developing highly advanced prototype assays for infectious and immune-related diseases on the fully automated IdyllaTM molecular diagnostics platform of Biocartis.
• Roche Diagnostics
• Becton, Dickinson, and Company
• bioMérieux SA
• Bio-Rad Laboratories, Inc.
• Dako (Agilent Technologies)
• FOUNDATION MEDICINE, INC.
• Genomic Health (Exact Sciences Corporation)
• Hologic, Inc.
• Illumina, Inc.
• HTG Molecular Diagnostics, Inc.
• Grifols, S.A.
• Siemens Healthcare GmbH
• Sysmex Corporation
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.
12 April 2021
Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.
09 April 2021
The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.
06 April 2021
Factors such as increasing data volumes for analysis, quick turnaround time for the discovery and development new drug, computing power, AI also helps in targeted manufacturing and others drive the market growth.